US Market Push Nyxoah is accelerating Genio's US commercial launch with about 110 million dollars in new capital, signaling readiness to scale in US hospitals and sleep clinics. This creates sales opportunities with healthcare systems, distribution partners, payer engagement, and real world evidence programs to drive reimbursement and adoption.

Genio Advantage Genio is a battery free hypoglossal neuromodulation device inserted through a single chin incision and controlled by a wearable, offering an attractive alternative to CPAP and other therapies. This differentiates Nyxoah in the OSA market and can be positioned to hospitals and specialists as a first line or rescue therapy, creating upsell opportunities with sleep clinics.

EU Funding Nyxoah has secured a 15 million euro tranche of an EIB loan and completed a large equity raise, underscoring validated growth funding and government backed support. This signals potential for European partnerships with hospitals and payers and could facilitate co financing or deployment programs within the EU.

Quality Regulation Nyxoah operates under ISO 13485 and maintains a quality driven product development approach, aligning with regulatory expectations which can accelerate hospital procurement and payer conversations.

Clinical Growth The company emphasizes clinical evidence showing best in class outcomes for reducing OSA burden, providing a solid foundation for clinical adoption in new markets. Opportunities include partnering with sleep labs, hospital systems, and researchers to run studies, publish results, and support reimbursement negotiations.